HitGen
Latest round
- Series B
Last raised
- May 2018
Total raised
- $39M
Investors
- 6
About HitGen
, develops technology platforms for the discovery and optimization of small molecules and nucleic acid based therapeutics. The company operates subsidiaries in Cambridge in the United Kingdom and Houston in the United States. In April 2020, HitGen completed an IPO on the Shanghai Stock Exchange under the ticker "688222". The company works with pharmaceutical and biotechnology organizations to provide drug discovery platforms including DNA encoded library technology, fragment based discovery, structure based design, and tools for nucleic acid based therapeutics. The company generates revenue through collaboration agreements, research service contracts and licensing of its drug discovery platforms. Following its IPO, HitGen Inc. plans to advance technologies that support the discovery and optimization of small molecule and nucleic acid based therapeutics.
Who invested in HitGen
6 investors across 3 rounds
See all investors in HitGen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about HitGen
Who invested in HitGen?
HitGen has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HitGen raised?
HitGen has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did HitGen last raise money?
HitGen's most recent round on record is a Series B, in May 2018.
What does HitGen do?
, develops technology platforms for the discovery and optimization of small molecules and nucleic acid based therapeutics.
Where is HitGen headquartered?
HitGen is headquartered in Chengdu, China.
Which VCs invest in companies like HitGen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at HitGen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like HitGen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.